These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

372 related articles for article (PubMed ID: 20584674)

  • 1. [Efficacy of zoledronic acid combined with chemotherapy in treatment of skeletal metastases of non-small cell lung cancer and the bone metabolic markers].
    Hu XY; Zou QF; Jin C; Li WD; Chen WS; Ma L
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Jun; 30(6):1343-6. PubMed ID: 20584674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
    Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
    J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.
    Orita Y; Sugitani I; Takao S; Toda K; Manabe J; Miyata S
    Ann Surg Oncol; 2015 Nov; 22(12):4008-13. PubMed ID: 25762482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
    Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
    Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
    Rajpar S; Massard C; Laplanche A; Tournay E; Gross-Goupil M; Loriot Y; Di Palma M; Bossi A; Escudier B; Chauchereau A; Fizazi K
    Ann Oncol; 2010 Sep; 21(9):1864-1869. PubMed ID: 20181574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
    Lipton A; Cook R; Saad F; Major P; Garnero P; Terpos E; Brown JE; Coleman RE
    Cancer; 2008 Jul; 113(1):193-201. PubMed ID: 18459173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.
    Broom RJ; Hinder V; Sharples K; Proctor J; Duffey S; Pollard S; Fong PC; Forgeson G; Harris DL; Jameson MB; O'Donnell A; North RT; Deva S; Hanning FJ; Grey A; Findlay MP
    Clin Genitourin Cancer; 2015 Feb; 13(1):50-8. PubMed ID: 25163397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
    Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
    Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
    Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
    J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zoledronic acid and survival in breast cancer patients with bone metastases and elevated markers of osteoclast activity.
    Lipton A; Cook RJ; Major P; Smith MR; Coleman RE
    Oncologist; 2007 Sep; 12(9):1035-43. PubMed ID: 17914073
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
    Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
    Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
    Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of intravenous zoledronic acid and oral ibandronate on early changes in markers of bone turnover in patients with bone metastases from non-small cell lung cancer.
    Francini F; Pascucci A; Bargagli G; Francini E; Conca R; Miano ST; Martellucci I; Migali C; Gotti G; Fiaschi AI; Cozzolino A; Petrioli R
    Int J Clin Oncol; 2011 Jun; 16(3):264-9. PubMed ID: 21240683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
    Langer C; Hirsh V
    Lung Cancer; 2010 Jan; 67(1):4-11. PubMed ID: 19939491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoledronic acid combined with chemotherapy in non-small cell lung cancer with bone metastasis.
    Zhang J; Wang LYJGJZYPM
    J BUON; 2021; 26(3):830-836. PubMed ID: 34268942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of zoledronic acid and strontium-89 in patients with asymptomatic bone metastases from non-small-cell lung cancer.
    Wang Y; Tao H; Yu X; Wang Z; Wang M
    Clin Lung Cancer; 2013 May; 14(3):254-60. PubMed ID: 23103352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study.
    Alcaraz A; González-López R; Morote J; de la Piedra C; Meseguer C; Esteban E; Climent M; González-Gragera B; Alvarez-Ossorio JL; Chirivella I; Mellado B; Lara PC; Vázquez F; Contreras JA; Carles J; Murias A; Calderero V; Comet-Batlle J; González-Del Alba A; León-Mateos L; Mañas A; Segarra J; Lassa A; González-Enguita C; Méndez MJ; Samper P; Unda M; Mahillo-Fernández I; Bellmunt J;
    Br J Cancer; 2013 Jul; 109(1):121-30. PubMed ID: 23799855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
    Fizazi K; Massard C; Smith M; Rader M; Brown J; Milecki P; Shore N; Oudard S; Karsh L; Carducci M; Damião R; Wang H; Ying W; Goessl C
    Eur Urol; 2015 Jul; 68(1):42-50. PubMed ID: 25449207
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Phase III clinical study of zoledronic acid in the treatment of pain induced by bone metastasis from solid tumor or multiple myeloma].
    Dong M; Feng FY; Zhang Y; Xie GR; Wang YJ; Liu JW; Song ST; Zhou QH; Ren J; Jiao SC; Li J; Wang XW; Chen Q; Wang ZH; Xu N; Feng JF
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):215-20. PubMed ID: 18756940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical response on bone metastasis from breast and lung cancer during treatment with zoledronic acid is inversely correlated to skeletal related events (SRE).
    Facchini G; Caraglia M; Santini D; Nasti G; Ottaiano A; Striano S; Maiolino P; Ruberto M; Fiore F; Tonini G; Budillon A; Iaffaioli RV; Zeppetella GL
    J Exp Clin Cancer Res; 2007 Sep; 26(3):307-12. PubMed ID: 17987788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.